Compare MLCI & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | RPTX |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.0M | 92.4M |
| IPO Year | N/A | 2020 |
| Metric | MLCI | RPTX |
|---|---|---|
| Price | $8.19 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 123.3K | ★ 1.3M |
| Earning Date | 03-13-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,823,000.00 | $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,122.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.13 | N/A |
| 52 Week Low | $6.97 | $0.89 |
| 52 Week High | $8.75 | $2.66 |
| Indicator | MLCI | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 75.13 |
| Support Level | N/A | $2.15 |
| Resistance Level | N/A | $2.66 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 84.91 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.